Abstract
The problem of comorbidity is becoming one of the main ones in modern clinical medicine, and the combination of bronchial asthma (BA) and cardiovascular diseases (CVD) is the most common in the general structure. Asthma is currently considered as an allergic disease of the respiratory tract, in which the inflammatory process plays a leading role. CVD is an inflammatory disease where type 2 cytokines often play a protective role. Numerous clinical studies demonstrate the relationship between allergic asthma and the risk of developing CVD, including coronary heart disease (CHD), atrial fibrillation, myocardial hypertrophy, arterial hypertension (AH). Mast cells, eosinophils, inflammatory cytokines, and immunoglobulin (Ig)E accumulate in the lungs of AD patients and in the damaged heart and blood vessels of CVD patients. Many drugs for the treatment of AD have been shown to affect the risk of CVD. Thus, allergic asthma and CVD may have common pathogenetic mechanisms. There is evidence that anti-asthma drugs have therapeutic potential in some CVDs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
